litlas
Log inCreate account

Corey J. Langer

Active 1993–2025

139
Papers
32,896
Citations
89
h-index
135
i10-index

Citations

Citations per year for Corey J. Langer1933: 1 citations1996: 4 citations1997: 10 citations1998: 10 citations1999: 11 citations2000: 21 citations2001: 25 citations2002: 47 citations2003: 103 citations2004: 108 citations2005: 165 citations2006: 158 citations2007: 215 citations2008: 197 citations2009: 262 citations2010: 264 citations2011: 280 citations2012: 250 citations2013: 230 citations2014: 217 citations2015: 198 citations2016: 179 citations2017: 251 citations2018: 299 citations2019: 946 citations2020: 1,067 citations2021: 998 citations2022: 680 citations2023: 491 citations2024: 759 citations2025: 372 citations2026: 12 citations1934–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,470 citing papers, 27.4% of this breakdownChina: 1,596 citing papers, 12.6% of this breakdownItaly: 693 citing papers, 5.5% of this breakdownUnited Kingdom: 597 citing papers, 4.7% of this breakdownJapan: 574 citing papers, 4.5% of this breakdownCanada: 543 citing papers, 4.3% of this breakdownFrance: 518 citing papers, 4.1% of this breakdownGermany: 514 citing papers, 4% of this breakdownSpain: 418 citing papers, 3.3% of this breakdownNetherlands: 371 citing papers, 2.9% of this breakdownAustralia: 315 citing papers, 2.5% of this breakdownSouth Korea: 293 citing papers, 2.3% of this breakdown
0%27.4%Other 21.9%

Institutions

Fields

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology2.3%
  • Physics and Astronomy1%
  • Engineering0.7%
  • Materials Science0.6%
  • Other2.7%

Topics

  • Lung Cancer Treatments and Mutations11.2%
  • Cancer Immunotherapy and Biomarkers8.2%
  • Lung Cancer Research Studies7%
  • Lung Cancer Diagnosis and Treatment6.1%
  • Cancer Genomics and Diagnostics3%
  • Head and Neck Cancer Studies2.1%
  • Other62.4%

Coauthors

All papers

Open in search
  1. Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

    Authors: Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana Davis, Maximillian Diehn, Josephine R. Giles, Alexander C. Huang, Wei‐Ting Hwang, Nancy R. Zhang, Adam J. Schoenfeld, Erica L. Carpenter, Corey J. Langer, E. John Wherry, Andy J. Minn - Science 2024 cited by 207

  2. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  3. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

    Authors: Charu Aggarwal, Jeffrey C. Thompson, Taylor A. Black, Sharyn I. Katz, Ryan Fan, Stephanie S. Yee, Austin L. Chien, Tracey L. Evans, Joshua Bauml, Evan Alley, Christine Ciunci, Abigail T. Berman, Roger B. Cohen, David Lieberman, Krishna S. Majmundar, Samantha L. Savitch, Jennifer J.D. Morrissette, Wei‐Ting Hwang, Kojo S.J. Elenitoba‐Johnson, Corey J. Langer, Erica L. Carpenter - JAMA Oncology 2018 cited by 490

  4. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

    Authors: Walter J. Curran, Rebecca Paulus, Corey J. Langer, R. Komaki, Jong Seok Lee, Stephen L. Hauser, B. Movsas, Todd H. Wasserman, Seth A. Rosenthal, Elizabeth Gore, Mitchell Machtay, William T. Sause, James D. Cox - JNCI Journal of the National Cancer Institute 2011 cited by 1,235

  5. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

    Authors: Joan H. Schiller, David Harrington, Chandra P. Belani, Corey J. Langer, Alan Sandler, James E. Krook, Junming Zhu, David H. Johnson - New England Journal of Medicine 2002 cited by 4,984

  6. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

    Authors: Andy Trotti, A. D. Colevas, A. Setser, Valerie W. Rusch, David P. Jaques, Volker Budach, Corey J. Langer, Brittany L. Murphy, Richard L. Cumberlin, C. Norman Coleman - Seminars in Radiation Oncology 2003 cited by 2,570

  7. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer

    Authors: Lova Sun, Benjamin Aaron Bleiberg, Wei‐Ting Hwang, Melina E. Marmarelis, Corey J. Langer, Aditi P. Singh, Roger B. Cohen, Ronac Mamtani, Charu Aggarwal - JAMA Oncology 2023 cited by 148

  8. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    Authors: Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromı́r Roubec, Luboš Petruželka, Libor Havel, Sujith Kalmadi, Jeffrey P. Ward, Zoran Andrić, Thierry Berghmans, David E. Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim G.J.V. Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey J. Langer - The Lancet Oncology 2023 cited by 101

  9. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

    Authors: Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer, Ali Tafreshi, Luis Paz‐Ares, Hans‐Georg Kopp, Jerónimo Rafael Rodríguez‐Cid, Dariusz M. Kowalski, Ying Cheng, Takayasu Kurata, Mark M. Awad, J. Lin, Bin Zhao, M. Catherine Pietanza, Bilal Piperdi, Marina Chiara Garassino - Journal of Thoracic Oncology 2021 cited by 183

  10. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

    Authors: Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, Panli Cardona, Emily Chan, Tracy Varrieur, Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong - Nature Medicine 2024 cited by 89

  11. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

    Authors: Luis Paz‐Ares, Alexander I. Spira, David Raben, David Planchard, Byoung Chul Cho, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Rina Hui, S. Murakami, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, A-M. Boothman, Helen Broadhurst, Catherine Wadsworth, P. Dennis, Scott Antonia, Corinne Faivre‐Finn - Annals of Oncology 2020 cited by 224

  12. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

    Authors: Jeffrey C. Thompson, Erica L. Carpenter, Benjamin A. Silva, J Rosenstein, Austin L. Chien, Katie Quinn, Carin R. Espenschied, Allysia J. Mak, Lesli A. Kiedrowski, Martina I. Lefterova, Rebecca J. Nagy, Sharyn I. Katz, Stephanie S. Yee, Taylor A. Black, Aditi P. Singh, Christine Ciunci, Joshua Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal - JCO Precision Oncology 2021 cited by 105

  13. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Authors: Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn, Karen L. Reckamp, Karin Holmskov Hansen, Sang‐We Kim, Rudolf M. Huber, Howard West, Harry J.M. Groen, Maximilian J. Hochmair, Natasha B. Leighl, Scott Gettinger, Corey J. Langer, Luis G. Paz-Ares Rodríguez, Egbert F. Smit, Edward S. Kim, William M. Reichmann, Frank G. Haluska, David Kerstein, D. Ross Camidge - Journal of Clinical Oncology 2017 cited by 583

  14. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

    Authors: Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey L. Evans, John A. Kosteva, Christine Ciunci, Peter Gabriel, Jeffrey C. Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby‐Sandy, Faith Mutale, Gloria A DiLullo, Roger B. Cohen, Anil Vachani, Corey J. Langer - Lung Cancer 2017 cited by 529

  15. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

    Authors: Joshua Bauml, Rosemarie Mick, Christine Ciunci, Charu Aggarwal, Christiana Davis, Tracey L. Evans, Charuhas Deshpande, Linda Miller, Pooja Patel, Evan Alley, Christina Knepley, Faith Mutale, Roger B. Cohen, Corey J. Langer - JAMA Oncology 2019 cited by 320

  16. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Authors: Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher - Journal of Thoracic Oncology 2017 cited by 243

  17. Clinicopathologic Features of Advanced Squamous NSCLC

    Authors: Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher - Journal of Thoracic Oncology 2016 cited by 197

  18. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

    Authors: Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih‐Hsin Yang, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew A. Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer - Journal of Thoracic Oncology 2020 cited by 183

  19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer

    Authors: Salma K. Jabbour, Abigail T. Berman, Roy H. Decker, Yong Lin, Steven J. Feigenberg, Scott Gettinger, Charu Aggarwal, Corey J. Langer, Charles B. Simone, Jeffrey D. Bradley, Joseph Aisner, Jyoti Malhotra - JAMA Oncology 2020 cited by 123

  20. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

    Authors: Jeffrey C. Thompson, Christiana Davis, Charuhas Deshpande, Wei‐Ting Hwang, Seth Jeffries, Alexander C. Huang, Tara C. Mitchell, Corey J. Langer, Steven Μ. Albelda - Journal for ImmunoTherapy of Cancer 2020 cited by 114

  21. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Authors: Charu Aggarwal, Melina E. Marmarelis, Wei‐Ting Hwang, Dylan Scholes, Tara McWilliams, Aditi P. Singh, Lova Sun, John A. Kosteva, Michael R. Costello, Roger B. Cohen, Corey J. Langer, Abigail Doucette, Peter Gabriel, Lawrence N. Shulman, Katharine A. Rendle, Jeffrey C. Thompson, Justin E. Bekelman, Erica L. Carpenter - JCO Precision Oncology 2023 cited by 44

  22. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

    Authors: Rudolf M. Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, Howard West, Karen L. Reckamp, Natasha B. Leighl, Marcello Tiseo, Egbert F. Smit, Dong‐Wan Kim, Scott Gettinger, Maximilian J. Hochmair, Sang-We Kim, Corey J. Langer, Myung‐Ju Ahn, Edward S. Kim, David Kerstein, Harry J.M. Groen, D. Ross Camidge - Journal of Thoracic Oncology 2019 cited by 144

  23. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

    Authors: Jeffrey C. Thompson, Wei‐Ting Hwang, Christiana Davis, Charuhas Deshpande, Seth Jeffries, Yashoda Rajpurohit, Vinod Krishna, Denis Smirnov, Raluca Verona, Matthew V. Lorenzi, Corey J. Langer, Steven Μ. Albelda - Lung Cancer 2019 cited by 142

  24. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

    Authors: Hossein Borghaei, Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Baerin Houghton, Takayasu Kurata, Ying Cheng, Jianxin Lin, M. Catherine Pietanza, Bilal Piperdi, Shirish M. Gadgeel - Cancer 2020 cited by 111